• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经降压素受体在前列腺癌细胞系中的表达及生理浓度下神经降压素的生长效应。

Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations.

作者信息

Seethalakshmi L, Mitra S P, Dobner P R, Menon M, Carraway R E

机构信息

Department of Physiology, University of Massachusetts Medical Center, Worcester 01655, USA.

出版信息

Prostate. 1997 May 15;31(3):183-92. doi: 10.1002/(sici)1097-0045(19970515)31:3<183::aid-pros7>3.0.co;2-m.

DOI:10.1002/(sici)1097-0045(19970515)31:3<183::aid-pros7>3.0.co;2-m
PMID:9167771
Abstract

BACKGROUND

Neurotensin (NT), a neuroendocrine peptide, exerts trophic effects in vivo and stimulates growth of some tumor cells in vitro. Androgen-sensitive prostate cells derived from lymph node carcinoma of the prostate (LNCaP) secrete NT and exhibit growth responses to NT. This study examines NT secretion, NT receptor and NT-growth responses in androgen-independent prostatic carcinoma (PC3) cells derived from prostate adenocarcinoma metastatic to bone.

METHODS

Binding of 125I-NT to PC3 membranes was studied by filtration. NT was measured by RIA. Reverse transcriptase polymerase chain reaction (RT-PCR) was used for NT and NT receptor mRNA. Growth was measured as 3H-thymidine incorporation into DNA.

RESULTS

Scatchard analyses gave two binding components (Kd1 = 40 pM and Kd2 = 300 pM) in equal amounts (15-30 x 10(3) sites/cell). The bioactive region of NT was essential and the specific, non-peptide NT antagonist, SR48692, inhibited (IC50 = 3 nM). GTP analogs, sodium ion and SH-directed alkylating agents also inhibited. Glutaraldehyde crosslinking labeled two substances (M(r) of 23 and 46 kDa). RT-PCR indicated robust expression of authentic NT receptor but little for NT precursor. NT was stable in PC3 cultures but it was not found in cells or conditioned media. Incubated with PC3 cells, NT exhibited a mitogenic effect with bell-shaped dose-response and maximum at 100 pM NT.

CONCLUSIONS

PC3 cells expressed genuine NT receptors and generated growth responses to physiologic levels of NT which were blocked by SR48692. If NT contributes to the survival of prostate tumor cells upon androgen deprivation therapy, NT antagonists might be useful agents in further treatment.

摘要

背景

神经降压素(NT)是一种神经内分泌肽,在体内发挥营养作用,并在体外刺激某些肿瘤细胞生长。源自前列腺淋巴结癌(LNCaP)的雄激素敏感前列腺细胞分泌NT,并对NT表现出生长反应。本研究检测了源自转移至骨的前列腺腺癌的雄激素非依赖性前列腺癌细胞(PC3)中的NT分泌、NT受体和NT生长反应。

方法

通过过滤研究125I-NT与PC3细胞膜的结合。用放射免疫分析法(RIA)测定NT。逆转录聚合酶链反应(RT-PCR)用于检测NT和NT受体mRNA。通过测定3H-胸腺嘧啶掺入DNA来检测细胞生长。

结果

Scatchard分析显示有两个等量的结合成分(Kd1 = 40 pM和Kd2 = 300 pM)(15 - 30×10(3)个位点/细胞)。NT的生物活性区域至关重要,特异性非肽类NT拮抗剂SR48692具有抑制作用(IC50 = 3 nM)。GTP类似物、钠离子和SH定向烷基化剂也有抑制作用。戊二醛交联标记了两种物质(分子量分别为23 kDa和46 kDa)。RT-PCR表明有活性的NT受体有较强表达,但NT前体表达较少。NT在PC3培养物中稳定,但在细胞或条件培养基中未检测到。与PC3细胞一起孵育时,NT表现出促有丝分裂作用,剂量反应呈钟形,在100 pM NT时达到最大值。

结论

PC3细胞表达真正的NT受体,并对生理水平的NT产生生长反应,而这种反应被SR48692阻断。如果NT在雄激素剥夺治疗中有助于前列腺肿瘤细胞的存活,NT拮抗剂可能是进一步治疗的有用药物。

相似文献

1
Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations.神经降压素受体在前列腺癌细胞系中的表达及生理浓度下神经降压素的生长效应。
Prostate. 1997 May 15;31(3):183-92. doi: 10.1002/(sici)1097-0045(19970515)31:3<183::aid-pros7>3.0.co;2-m.
2
Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692.非肽类神经降压素受体拮抗剂SR48692对神经降压素诱导的胰腺癌生长的抑制作用
Cancer. 1997 May 1;79(9):1787-93. doi: 10.1002/(sici)1097-0142(19970501)79:9<1787::aid-cncr22>3.0.co;2-t.
3
Regulation of neurotensin receptor function by the arachidonic acid-lipoxygenase pathway in prostate cancer PC3 cells.花生四烯酸-脂氧合酶途径对前列腺癌PC3细胞中神经降压素受体功能的调节
Prostaglandins Leukot Essent Fatty Acids. 2006 Feb;74(2):93-107. doi: 10.1016/j.plefa.2005.11.005. Epub 2006 Jan 6.
4
Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress.神经降压素受体结合以及神经降压素诱导的前列腺癌PC3细胞生长信号传导对代谢应激敏感。
Regul Pept. 2007 Jun 7;141(1-3):140-53. doi: 10.1016/j.regpep.2006.12.027. Epub 2007 Jan 16.
5
Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway.神经降压素通过一条新的c-Src/Stat5b信号通路刺激前列腺癌细胞的有丝分裂。
Oncogene. 2007 Feb 1;26(5):745-56. doi: 10.1038/sj.onc.1209814. Epub 2006 Jul 24.
6
Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.神经降压素是一种在人类前列腺癌中受雄激素撤除刺激的自分泌营养因子。
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4673-7. doi: 10.1073/pnas.91.11.4673.
7
Relevant genomics of neurotensin receptor in cancer.癌症中神经降压素受体的相关基因组学
Anticancer Res. 2000 Jan-Feb;20(1A):53-8.
8
Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells.丝裂原活化蛋白激酶、磷脂酰肌醇-3激酶和表皮生长因子受体在神经降压素对PC3细胞DNA合成的刺激作用中的参与。
Regul Pept. 2004 Aug 15;120(1-3):155-66. doi: 10.1016/j.regpep.2004.03.004.
9
Differential expression of new splice variants of the neurotensin receptor 1 gene in human prostate cancer cell lines.神经降压素受体 1 基因新剪接变体在人前列腺癌细胞系中的差异表达。
Peptides. 2010 Feb;31(2):242-7. doi: 10.1016/j.peptides.2009.12.007. Epub 2009 Dec 14.
10
Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.评估神经降压素受体 1 作为前列腺癌治疗诊断应用的潜在生物标志物。
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2199-2207. doi: 10.1007/s00259-019-04355-y. Epub 2019 Jul 1.

引用本文的文献

1
Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.神经降压素及其在女性激素敏感性癌症中的作用。
Int J Mol Sci. 2024 Oct 30;25(21):11648. doi: 10.3390/ijms252111648.
2
Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics.用于前列腺癌诊疗的NT-PSMA异二价探针的合理设计。
RSC Med Chem. 2024 Sep 16;15(12):4153-8. doi: 10.1039/d4md00491d.
3
GPCR-Gα13 Involvement in Mitochondrial Function, Oxidative Stress, and Prostate Cancer.G 蛋白偶联受体-Gα13 参与线粒体功能、氧化应激和前列腺癌。
Int J Mol Sci. 2024 Jun 28;25(13):7162. doi: 10.3390/ijms25137162.
4
Synthesis of Cu-, Co-, and Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.合成用于神经降压素受体 1 靶向治疗学的 Cu、Co 和 Ga 标记放射性药物:使用多胺大环调整体内分布。
J Nucl Med. 2024 Aug 1;65(8):1250-1256. doi: 10.2967/jnumed.124.267469.
5
Chelator boosted tumor-retention and pharmacokinetic properties: development of Cu labeled radiopharmaceuticals targeting neurotensin receptor.螯合剂增强肿瘤保留和药代动力学特性:神经降压素受体靶向的 Cu 标记放射性药物的开发。
Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3322-3333. doi: 10.1007/s00259-024-06754-2. Epub 2024 May 21.
6
Neurotensin (8-13) and Neuromedin N Neuropeptides Radiolabelling with Copper-64 Produced on Solid or Liquid Targets.神经降压素(8-13)和神经肽 N 放射性标记用固体或液体靶材生产的铜-64。
Molecules. 2024 Mar 20;29(6):1390. doi: 10.3390/molecules29061390.
7
Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms.前列腺的神经内分泌细胞:组织学、生物学功能及分子机制
Precis Clin Med. 2021 Jan 28;4(1):25-34. doi: 10.1093/pcmedi/pbab003. eCollection 2021 Mar.
8
Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.评估神经降压素受体 1 作为前列腺癌治疗诊断应用的潜在生物标志物。
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2199-2207. doi: 10.1007/s00259-019-04355-y. Epub 2019 Jul 1.
9
Validation of Neurotensin Receptor 1 as a Therapeutic Target for Gastric Cancer.神经降压素受体 1 作为胃癌治疗靶点的验证。
Mol Cells. 2018 Jun;41(6):591-602. doi: 10.14348/molcells.2018.0025. Epub 2018 May 24.
10
Imaging Neurotensin Receptor in Prostate Cancer With Cu-Labeled Neurotensin Analogs.用铜标记的神经降压素类似物对前列腺癌中的神经降压素受体进行成像。
Mol Imaging. 2017 Jan-Dec;16:1536012117711369. doi: 10.1177/1536012117711369.